What Is the Next Frontier in Cardiac Amyloidosis Radionuclide Imaging?

The Editor’s Choice study in the May 2025 issue of the Journal of Nuclear Cardiology (JNC) examines whether a left ventricular myocardium-to-blood ratio (LV MBR) obtained through ^99mTc-HMDP SPECT/CT is a valid alternative to a heart-to-contralateral lung (H/CL) ratio in the diagnosis of cardiac amyloidosis.

The findings by Olli Suomalainen, MD, et al. support adoption of quantitative amyloidosis imaging as a complement to, or even an improvement over, visual scoring; however, an accompanying editorial suggests that software advancements are paving the way for another new frontier in cardiac amyloidosis radionuclide imaging. Editorialists Dominik C. Benz, MD, and Sarah A.M. Cuddy, MD, predict this new frontier will usher in “a more precise, objective, and reproducible measurement of myocardial radiotracer uptake.”

What is this new frontier? FIND OUT NOW.

If you are already logged into your ASNC account, access JNC here.

Log in to View JNC